Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17742
Country/Region: Nigeria
Year: 2014
Main Partner: Gembu Center for AIDS Advocacy Nigeria
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $5,616,145 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The cornerstone of FGHiN-SUCCESS programming is increasing access of HIV services to vulnerable communities and ensuring ownership and sustainability of services in supported clinics and communities. We will actively scale up comprehensive HIV services to additional LGAs in Kaduna State to achieve full saturation targeting key and priority population activities and strengthen community outreach activities in this tier 1 state for increased demand creation. Passive enrollment of clients into PMTCT and treatment programs will continue in Kano, Gombe and Kogi states. We will implement our program in close collaboration with the states’ HIV/AIDS programs to ensure compliance with their strategic plans. We will carry out joint planning, implementation and monitoring activities with respective states MoH and related agencies to ensure quality and sustainability of services. FGHiN will continue to implement high quality ARV treatment services for HIV-infected adult and pediatric patients, including clinical monitoring, quality laboratory evaluation and monitoring services, and treatment adherence activities, in accordance with the national guidelines and PEPFAR priorities. Community support systems will be built to complement HIV care and support activities and enhance quality of life of PLWAs in Kaduna state. We will establish and strengthen communication and referral linkages between health facilities as well as with community programs. HIV prevention services will utilize a combination prevention approach including PHDP. Our program will implement and adhere to health care waste management policies and procedures in all our supported facilities

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $750,100
Care: Orphans and Vulnerable Children (HKID) $235,132
Care: TB/HIV (HVTB) $270,381
Care: Pediatric Care and Support (PDCS) $50,804
Laboratory Infrastructure (HLAB) $601,638
Biomedical Prevention: Injection Safety (HMIN) $25,000
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $474,452
Sexual Prevention: Other Sexual Prevention (HVOP) $341,250
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $544,341
Treatment: Adult Treatment (HTXS) $2,172,332
Treatment: Pediatric Treatment (PDTX) $150,715
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age: 0-9 2015 4
GEND_GBV Age: 10-14 2015 9
GEND_GBV Age: 15-17 2015 12
GEND_GBV Age: 18-24 2015 8
GEND_GBV Age: 25+ 2015 4
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 29
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 8
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 29
GEND_GBV Number of people receiving post-GBV care 2015 37
GEND_GBV Sex: Female 2015 25
GEND_GBV Sex: Male 2015 12
GEND_GBV Sum of Age disaggregates 2015 37
GEND_GBV Sum of Sex disaggregates 2015 37
GEND_NORM By Age: 0-9 2015 207
GEND_NORM By Age: 10-14 2015 207
GEND_NORM By Age: 15-19 2015 497
GEND_NORM By Age: 20-24 2015 1,242
GEND_NORM By Age: 25+ 2015 1,988
GEND_NORM By Sex: Female 2015 2,112
GEND_NORM By Sex: Male 2015 2,029
GEND_NORM By type of activity: Community-level 2015 2,899
GEND_NORM By type of activity: Individual 2015 414
GEND_NORM By type of activity: Small Group 2015 828
GEND_NORM Number of people completing an intervention pertaining to gender norms, that meets minimum criteria 2015 4,141
GEND_NORM Sum of Age disaggregates 2015 4,141
GEND_NORM Sum of Sex disaggregates 2015 4,141
HTS_TST Age/sex: <1 Female 2015 813
HTS_TST Age/sex: <1 Female 2015 813
HTS_TST Age/sex: <1 Male 2015 782
HTS_TST Age/sex: <1 Male 2015 782
HTS_TST Age/sex: 1-4 Female 2015 909
HTS_TST Age/sex: 1-4 Female 2015 909
HTS_TST Age/sex: 1-4 Male 2015 868
HTS_TST Age/sex: 1-4 Male 2015 868
HTS_TST Age/sex: 10-14 Female 2015 806
HTS_TST Age/sex: 10-14 Female 2015 806
HTS_TST Age/sex: 10-14 Male 2015 785
HTS_TST Age/sex: 10-14 Male 2015 785
HTS_TST Age/sex: 15-19 Female 2015 13,036
HTS_TST Age/sex: 15-19 Female 2015 13,036
HTS_TST Age/sex: 15-19 Male 2015 8,708
HTS_TST Age/sex: 15-19 Male 2015 8,708
HTS_TST Age/sex: 20-24 Female 2015 32,642
HTS_TST Age/sex: 20-24 Female 2015 32,642
HTS_TST Age/sex: 20-24 Male 2015 18,025
HTS_TST Age/sex: 20-24 Male 2015 18,025
HTS_TST Age/sex: 25-49 Female 2015 80,737
HTS_TST Age/sex: 25-49 Female 2015 80,737
HTS_TST Age/sex: 25-49 Male 2015 56,628
HTS_TST Age/sex: 25-49 Male 2015 56,628
HTS_TST Age/sex: 5-9 Female 2015 362
HTS_TST Age/sex: 5-9 Female 2015 362
HTS_TST Age/sex: 5-9 Male 2015 351
HTS_TST Age/sex: 5-9 Male 2015 351
HTS_TST Age/sex: 50+ Female 2015 1,808
HTS_TST Age/sex: 50+ Female 2015 1,808
HTS_TST Age/sex: 50+ Male 2015 1,756
HTS_TST Age/sex: 50+ Male 2015 1,756
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,890
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 2,786
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 128,223
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 85,117
HTS_TST Aggregated Age/sex: <15 Female 2015 2,890
HTS_TST Aggregated Age/sex: <15 Male 2015 2,786
HTS_TST Aggregated Age/sex: 15+ Female 2015 128,223
HTS_TST Aggregated Age/sex: 15+ Male 2015 85,117
HTS_TST By Test Result: Negative 2015 212,632
HTS_TST By Test Result: Negative 2015 212,632
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 219,016
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 219,016
HTS_TST Sum of Age/Sex disaggregates 2015 219,016
HTS_TST Sum of Age/Sex disaggregates 2015 219,016
HTS_TST Sum of Aggregated Age/Sex <15 2015 5,676
HTS_TST Sum of Aggregated Age/Sex <15 2015 5,676
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 213,340
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 213,340
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 219,016
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 219,016
HTS_TST Sum of Test Result disaggregates 2015 219,016
HTS_TST Sum of Test Result disaggregates 2015 219,016
HTS_TST_POS By Test Result: Positive 2015 6,384
HTS_TST_POS By Test Result: Positive 2015 6,384
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 1
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 1
LAB_ACC Sum of Support Type disaggregates 2015 1
LAB_CAP By clinical laboratories 2015 15
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 15
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 15
LAB_CAP Sum of Site Support Type disaggregates 2015 15
OVC_ACC Age: <1 2015 146
OVC_ACC Age: 1-4 2015 608
OVC_ACC Age: 10-14 2015 584
OVC_ACC Age: 15-17 2015 340
OVC_ACC Age: 18+ 2015 73
OVC_ACC Age: 5-9 2015 681
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 2,432
OVC_ACC Sex: Female 2015 1,240
OVC_ACC Sex: Male 2015 1,192
OVC_ACC Sum of Age disaggregates 2015 2,432
OVC_ACC Sum of Sex disaggregates 2015 2,432
OVC_SERV Age: <1 2015 486
OVC_SERV Age: 1-4 2015 2,027
OVC_SERV Age: 10-14 2015 1,947
OVC_SERV Age: 15-17 2015 1,135
OVC_SERV Age: 18+ 2015 243
OVC_SERV Age: 5-9 2015 2,270
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 8,108
OVC_SERV Sex: Female 2015 4,135
OVC_SERV Sex: Male 2015 3,973
OVC_SERV Sum of Age disaggregates 2015 8,108
OVC_SERV Sum of Sex disaggregates 2015 8,108
PMTCT_ARV Life-long ART (including Option B+) 2015 877
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 80
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 638
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 1,753
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 1,595
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 580
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 297
PMTCT_ARV Sum of New and Current disaggregates 2015 877
PMTCT_ARV Sum of Regimen Type disaggregates 2015 1,595
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 877
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 80
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 638
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 1,753
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 1,595
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 580
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 297
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 877
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 1,595
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 526
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 1,069
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 80
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 1,595
PMTCT_EID Sum of Infant Age disaggregates 2015 1,595
PMTCT_STAT By: Known positives at entry 2015 701
PMTCT_STAT By: Number of new positives identified 2015 1,052
PMTCT_STAT Number of new ANC and L&D clients 2015 44,359
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 40,367
PMTCT_STAT Sum of Positives Status disaggregates 2015 1,753
PMTCT_STAT_NGI By: Known positives at entry 2015 701
PMTCT_STAT_NGI By: Number of new positives identified 2015 1,052
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 44,359
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 40,367
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 1,753
PP_PREV Age/sex: 10-14 Female 2015 1,252
PP_PREV Age/sex: 10-14 Male 2015 1,203
PP_PREV Age/sex: 15-19 Female 2015 1,502
PP_PREV Age/sex: 15-19 Male 2015 1,443
PP_PREV Age/sex: 20-24 Female 2015 3,755
PP_PREV Age/sex: 20-24 Male 2015 3,609
PP_PREV Age/sex: 25-49 Female 2015 5,634
PP_PREV Age/sex: 25-49 Male 2015 5,413
PP_PREV Age/sex: 50+ Female 2015 376
PP_PREV Age/sex: 50+ Male 2015 361
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 24,548
PP_PREV Sum of Age/Sex disaggregates 2015 24,548
PP_PREV Total number of people in the target population 2015 89,185
SITE_SUPP By program area/support type: Care and Support Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: Food and Nutrition Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: General Population Prevention Direct Service Delivery (DSD) 2015 155
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD) 2015 155
SITE_SUPP By program area/support type: Key Populations Prevention Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: OVC Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) 2015 155
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 155
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: VMMC Direct Service Delivery (DSD) 2015 15
TB_ART Age: 0-4 2015 8
TB_ART Age: 15+ 2015 706
TB_ART Age: 5-14 2015 38
TB_ART Aggregated Age: <15 2015 45
TB_ART Aggregated Age: 15+ 2015 707
TB_ART Female 2015 384
TB_ART Known HIV-positive 2015 323
TB_ART Male 2015 368
TB_ART Newly tested 2015 429
TB_ART Sum of Aggregated Age disaggregates 2015 752
TB_ART Sum of Sex disaggregates 2015 752
TB_ART Sum of Test Status disaggregates 2015 752
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 752
TB_SCREEN Age: <1 2015 630
TB_SCREEN Age: 1-4 2015 315
TB_SCREEN Age: 10-14 2015 315
TB_SCREEN Age: 15-19 2015 3,150
TB_SCREEN Age: 20-24 2015 7,875
TB_SCREEN Age: 25-49 2015 17,324
TB_SCREEN Age: 5-9 2015 630
TB_SCREEN Age: 50+ 2015 1,260
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 1,890
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 29,609
TB_SCREEN Sex: Female 2015 22,049
TB_SCREEN Sex: Male 2015 9,450
TB_SCREEN Sum of Age disaggregates 2015 5,040
TB_SCREEN Sum of Aggregated Age disaggregates 2015 31,499
TB_SCREEN Sum of Sex disaggregates 2015 31,499
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 31,499
TX_CURR Age/Sex: <1 Female 2015 32
TX_CURR Age/Sex: <1 Male 2015 37
TX_CURR Age/Sex: 1-4 Female 2015 153
TX_CURR Age/Sex: 1-4 Male 2015 173
TX_CURR Age/Sex: 15+ Female 2015 11,731
TX_CURR Age/Sex: 15+ Male 2015 5,779
TX_CURR Age/Sex: 5-14 Female 2015 278
TX_CURR Age/Sex: 5-14 Male 2015 314
TX_CURR Aggregated Age/Sex: <1 Female 2015 32
TX_CURR Aggregated Age/Sex: <1 Male 2015 37
TX_CURR Aggregated Age/Sex: <15 Female 2015 463
TX_CURR Aggregated Age/Sex: <15 Male 2015 523
TX_CURR Aggregated Age/Sex: 15+ Female 2015 11,732
TX_CURR Aggregated Age/Sex: 15+ Male 2015 5,779
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 18,497
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 5
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 66
TX_CURR Sum of age/sex disaggregates 2015 987
TX_CURR Sum of Aggregated Age/Sex <15 2015 986
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 17,511
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 18,497
TX_CURR_NGI Age/Sex: <1 Female 2015 32
TX_CURR_NGI Age/Sex: <1 Male 2015 37
TX_CURR_NGI Age/Sex: 1-4 Female 2015 153
TX_CURR_NGI Age/Sex: 1-4 Male 2015 173
TX_CURR_NGI Age/Sex: 15+ Female 2015 11,732
TX_CURR_NGI Age/Sex: 15+ Male 2015 5,779
TX_CURR_NGI Age/Sex: 5-14 Female 2015 277
TX_CURR_NGI Age/Sex: 5-14 Male 2015 314
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 32
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 37
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 463
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 523
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 11,732
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 5,779
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 18,497
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 18,497
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 986
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 17,511
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 18,497
TX_NEW Aggregated Grouping by Age: <1 Male 2015 51
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 119
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 273
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 117
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 4,854
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 2,080
TX_NEW Breastfeeding status 2015 243
TX_NEW By Age/Sex: <1 Female 2015 119
TX_NEW By Age/Sex: <1 Male 2015 51
TX_NEW By Age/Sex: 1-4 Female 2015 87
TX_NEW By Age/Sex: 1-4 Male 2015 37
TX_NEW By Age/Sex: 10-14 Female 2015 26
TX_NEW By Age/Sex: 10-14 Male 2015 11
TX_NEW By Age/Sex: 15-19 Female 2015 513
TX_NEW By Age/Sex: 15-19 Male 2015 220
TX_NEW By Age/Sex: 20-24 Female 2015 769
TX_NEW By Age/Sex: 20-24 Male 2015 330
TX_NEW By Age/Sex: 25-49 Female 2015 3,333
TX_NEW By Age/Sex: 25-49 Male 2015 1,428
TX_NEW By Age/Sex: 5-9 Female 2015 41
TX_NEW By Age/Sex: 5-9 Male 2015 18
TX_NEW By Age/Sex: 50+ Female 2015 239
TX_NEW By Age/Sex: 50+ Male 2015 103
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 7,325
TX_NEW Pregnancy status 2015 485
TX_NEW Sum of Age/Sex disaggregates 2015 7,325
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 7,324
Cross Cutting Budget Categories and Known Amounts Total: $250,760
Renovation $99,747
Gender: Gender Equality $23,513
Promoting gender-related policies and laws that increase legal protection
Implementation
Motor Vehicles: Purchased $127,500
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Child Survival Activities
Mobile Populations
Safe Motherhood
Tuberculosis
Family Planning